Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Neuropharmacology. 2015 Mar 4;95:121–129. doi: 10.1016/j.neuropharm.2015.02.023

Fig. 2.

Fig. 2

Effect of VU0364770 and LSP1-2111 on haloperidol-induced catalepsy. Both VU0364770 (A, s.c. administration) and LSP1-2111 (B, i.p. administration) dose-dependently reduced catalepsy induced by haloperidol (1.5 mg/kg, i.p.). The maximum effect achieved by both drugs, was comparable to that of the A2A antagonist (56.6 mg/kg; white bar), that was used as a positive comparator drug in this experiment. (n = 10 for VU0364770; n = 10 for LSP1-2111 treated group) p < 0.05, * vs. vehicle, Dunnett's test.